

Supplemental Material

List of Investigators

United States: Akright, Laura; Ballantyne, Christie; Baum, Seth; Bays, Harold; Bogle, Tanya; Cox, Michael; Garla, Vishnu; Kivitz, Alan; Leibowitz, Mark; Lepor, Norman; Makam, Sashi; Rosen, Jeffrey; Rosenstock, Julio; Rudolph, Lance; Scott, John; Shah, Amit; Shin, Elliot; Stumbris, Ronald; Toth, Phillip; Wayne, Jeffrey; Mexico: Aguilar Martinez, Maria; Aguilar Salinas, Carlos; Choza Romero, Ricardo; Garcia Reza, Raymundo; Gonzalez Galvez, Guillermo; Guillermo; Medina, Carlos; Mendez Machado, Gustavo; Vidrio, Maricela; Salmón, Violante Ortiz, Rafael; Germany: Appel, Karl-Friedrich; Jeserich, Michael; Kassner, Ursula. Laufs, Ulrich ; Vogt, Anja; Norway: Asprusten, Emil; Atar, Dan; Gullestad, Lars; Heggen, Eli; Lappegard, Knut. Ponitz, Volker; Ruddox, Vidar; Schirmer, Henrik; Turkey: Cavusoglu, Yuksel; Kayikcioglu, Latife. Ozer, Necla; United Kingdom: Clark, Rebecca; Hartland, Andrew; McCallum, Linsay Nair, Devaki; Saxena, Manish; Japan: Akabame, Satoshi; Inoue, Satoshi; Kitada, Hirokazu; Matsuoka, Osamu; Mizuyama, Kazuyuki; Nakashima, Eitaro; Sekino, Hisakuni; Tanaka, Hideki; South Korea: Choi, Seung-Hyuk; Lee, Sanghak; Kang, Hyun-Jae; Nam, Chang-Wook.

List of Investigational Review Boards and Independent Ethics Committees

Advarra 6100 Merriweather Drive Suite 600 Columbia, MD 21044 USA
Comité de Investigación del Hospital La Misión, S.A. de C.V. 112 Avenida Avenida Del Hospital 1° y 2° piso Monterrey, Nuevo Leon 64718 Mexico
Comité de Ética en Investigación del Centro de Investigación Farmacéutica Especializada de Occidente 1670 Avenida Ignacio Luis Vallarta Colonia Americana Guadalajara, Jalisco 44160 Mexico
Comite de etica en investigacion del Hospital Angeles Mocel 29 Calle Gobernador Gregorio V. Gelati Ciudad de México, Distrito Federal 11850 Mexico
Médica SUR,S.A.B. de C.V. 150 Puente de Piedra Ciudad de México, Distrito Federal 14050 Mexico
Comité de Ética en Investigación Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V Volcán Popocatepetl #3352 Zapopan, Jalisco 45070 Mexico
Instituto Jalisciense de Investigación Clínica S.A. de C.V. 20 Calle Penitenciaría Guadalajara, Jalisco 44100 Mexico
Comite de Etica en Investigación y Comite de Investigación del Hospital Ángeles MOCEL Gelati No. 29 piso 1 , Col. San Miguel Chapultepec Piso 1, anexo 1 CDMX, Distrito Federal 11850 Mexico

Comité de Ética y Comité de Investigación de Medical Care and Research S.A de C.V Calle 32 por 11 y 13 N/A Mérida, Yucatan 97070 Mexico
Comite de Etica del Instituto Nacional de Ciencias Medicas y Nutricion SZ Av vasco de quiroga 15, belisario dominguez Sec XVI Mexico City, Distrito Federal 14080 Mexico
PROMOTORA MEDICA AGUASCALIENTES S.A DE C.V REPUBLICA DE ECUADOR 200, LAS AMERICAS AGUASCALIENTES, Aguascalientes 20230 Mexico
Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig Geschäftsstelle c/o Zentrale Poststelle Liebigstraße 18 Leipzig, Sachsen 04103 Germany
Ethikkommission der Landesärztekammer Hessen Haunauer Landstrasse 152 Frankfurt am Main, Hessen 60314 Germany Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig Geschäftsstelle c/o Zentrale Poststelle Liebigstraße 18 Leipzig, Sachsen 04103 Germany
Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig Geschäftsstelle c/o Zentrale Poststelle Liebigstraße 18 Leipzig, Sachsen 04103 Germany
REK south-east B Gullhaugveien 1-3 Oslo, Oslo 0484 Norway
Ege University Fac. of Medicine Ethics Committee Ege UTF Tip Fak. Dekanlik Binasi 2. Kat Izmir, Izmir 35100 Turkiye

London - Hampstead Research Ethics Committee 4 Munshull Street Barlow House. 3rd Floor Manchester, Manchester M1 3DZ UK
Medical Corporation Heishinkai OPHAC Hospital IRB 4-1-29 Osaka-shi, Osaka 532-0003 Japan
Doujin Memorial Medical Foundation, Meiwa Hospital IRB 1-18, Kandasudacho Chiyoda-ku, Tokyo 101-0041 Japan
Sekino Hospital Institutional Review Board Ikebukuro Toshima-ku, Tokyo Japan
Adachikyousai Hospital Institutional Review Board 1-36-8 Yanagihara, Adachi-ku N/A, Tokyo 120-0022 Japan
Review Board of Human Rights and Ethics for Clinical Studies 2-2-1, Kyobashi Chuo-ku, Tokyo 104-0031 Japan
HURECS IRB 2-2-1, Kyobashi Chuo-ku, Tokyo 104-0031 Japan
Samsung Medical Center Institutional Review Board 81 Irwon-ro Seoul, Seoul 06351 South Korea
Severance Hospital Institutional Review Board 50-1 Yonsei-ro, Seodaemun-gu Jejung Hall 2F seoul, Seoul 03722 South Korea

Institutional review board of Seoul National University Hospital
101, Daehak-ro Jongno-gu
IRB office, Center for Human Research Protection
Seoul, Seoul 03080
South Korea

Keimyung University Dongsan Hospital Institutional Review Board
1035, Dalgubeol-daero, Dalseo-gu
8th Floor IRB
Daegu, Taegu-Kwangyokshi 42601
South Korea

Supplemental Table 1 - Additional Exploratory Lipid Efficacy Endpoints

	MK-0616	MK-0616	MK-0616	MK-0616	
	6 mg QD	12 mg QD	18 mg QD	30 mg QD	Placebo
HDL-C					
Number of participants evaluated	74	76		73	72
Mean ± SD percent change from baseline in HDL-C at Week 8	-0.2 ± 11.0	4.1 ± 13.4	6.1 ± 15.4	1.3 ± 13.0	1.9 ± 16.1
Difference in LS means vs. placebo (95% CI)	-2.1 (-6.6, 2.4)	2.2 (-2.6, 7.0)	4.2 (-1.0, 9.3)	-0.6 (-5.4, 4.2)	
Total Cholesterol					
Number of participants evaluated	75	76	74	73	74
Mean ± SD percent change from baseline in Total Cholesterol at Week 8	-24.9 ± 17.4	-34.6 ± 16.4	-36.6 ± 11.3	-39.4 ± 14.4	2.1 ± 14.3
Difference in LS means vs. placebo (95% CI)	-27.0 (-32.1, -21.8)	-36.7 (-41.7, -31.7)	-38.7 (-42.9, -34.5)	-41.5 (-46.2, -36.8)	--
Triglycerides					
Number of participants evaluated	77	76	76	76	75

Mean $\pm$ SD percent change from baseline in Triglycerides at Week 8	0.8 $\pm$ 30.4	-4.9 $\pm$ 37.6	-7.7 $\pm$ 33.6	-7.3 $\pm$ 38.2	8.5 $\pm$ 42.0
Difference in LS means vs. placebo (95% CI)	-7.7 (-19.7, 4.3)	-13.5 (-26.4, -0.5)	-16.2 (-28.6, -3.8)	-15.8 (-29.0, -2.7)	--

VLDL-C

Number of participants evaluated	77	74	75	74	74
Mean $\pm$ SD percent change from baseline in VLDL-C at Week 8	1.4 $\pm$ 30.9	-6.1 $\pm$ 32.4	-6.0 $\pm$ 33.5	-5.5 $\pm$ 37.6	7.5 $\pm$ 36.6)
Difference in LS means vs. placebo (95% CI)	-6.2 (-17.3, 4.9)	-13.6 (-25.0, -2.2)	-13.5 (-25.1, -1.9)	-13.0 (-25.4, -0.7)	--

HDL-C = High Density Lipoprotein Cholesterol; VLDL-C = Very Low Density Lipoprotein Cholesterol

Supplemental Table 2 – Summary of Adverse Events During the 8-Week Treatment Period (Not Including the 8-Week Safety Follow-Up Period)

	MK-0616	MK-0616	MK-0616	MK-0616		
	6 mg QD	12 mg QD	18 mg QD	30 mg QD	Placebo	Total
Parameter	(N=77)	(N=76)	(N=76)	(N=76)	(N=75)	(N=380)
n (%) of participants with:						
≥1 AE	29 (37.7)	27 (35.5)	31 (40.8)	28 (36.8)	30 (40.0)	145 (38.2)
Discontinued intervention due to an AE	2 (2.6)	0 (0.0)	2 (2.6)	2 (2.6)	1 (1.3)	7 (1.8)
Serious AEs	0 (0.0)	1 (1.3)	2 (2.6)	2 (2.6)	0 (0.0)	5 (1.3)
Moderate or severe AEs	9 (11.7)	6 (7.9)	9 (11.8)	11 (14.5)	8 (10.7)	43 (11.3)
Intervention-related AEs*	3 (3.9)	11 (14.5)	11 (14.5)	8 (10.5)	6 (8.0)	39 (10.3)
Deaths	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	1 (0.3)


Most Common AEs (incidence of > 5% within a treatment group, n(%))


Arthralgia	0 (0.0)	4 (5.3)	1 (1.3)	1 (1.3)	1 (1.3)	7 (1.8)
COVID-19	6 (7.8)	1 (1.3)	2 (2.6)	2 (2.6)	5 (6.7)	16 (4.2)
Diarrhea	4 (5.2)	1 (1.3)	2 (2.6)	0 (0.0)	1 (1.3)	8 (2.1)


Dyspepsia	1 (1.3)	5 (6.6)	3 (3.9)	0 (0.0)	1 (1.3)	10 (2.6)
Fatigue	0 (0.0)	3 (3.9)	1 (1.3)	0 (0.0)	4 (5.3)	8 (2.1)
Nausea	1 (1.3)	1 (1.3)	4 (5.3)	1 (1.3)	0 (0.0)	7 (1.8)

* Deemed by the investigator to be possibly, probably, or definitely related to study medication.

Supplemental Figure 1 - Difference in Mean Percent Change from Baseline (95% CI) in LDL-C (MK-0616 vs. Placebo) at Week 8 by Subgroup







BMI = Body Mass Index

eGFR = estimated glomerular filtration rate

Risk Categories are defined as the following: included the following:

- Clinical ASCVD: LDL-C <70 mg/dL (<1.81 mmol/L)
- Intermediate/High ASCVD Risk: LDL-C <100 mg/dL (<2.59 mmol/L) in participants with an ASCVD risk-equivalent and/or a 10-year risk of having an ASCVD event that is ≥7.5%;
- Borderline ASCVD risk: LDL-C <130 mg/dL (<3.37 mmol/L) in participants with a 10-year risk of having an ASCVD event that is ≥5.0% and <7.5%.